Single cell Analysis Market

Inquire Now to get the Global Forecasts Data upto 2029

The global single cell analysis market in terms of revenue was estimated to be worth $3.5 billion in 2023 and is poised to reach $7.1 billion by 2028, growing at a CAGR of 15.3% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Various elements such as rising prevalence of cancer, increasing R&D in the pharmaceutical & biotechnology industries for complex diseases, and the technological advancements, are driving the market growth.

Attractive Opportunities in the Single Cell Analysis Market

To know about the assumptions considered for the study, Request for Free Sample Report

Single Cell Analysis Market Dynamics

DRIVER: Growing prevalence of cancer

Single-cell analysis plays a crucial role in identifying biomarkers associated with cancer. According to GLOBOCAN, the number of cancer cases will rise to approximately 30 million by 2040. Cancer is a highly heterogeneous disease, characterized by diverse cell populations within a tumor. Single-cell analysis enables researchers to dissect this heterogeneity and study individual cancer cells at the molecular level. By analyzing gene expression, genetic mutations, and other cellular characteristics at the single-cell level, researchers gain a comprehensive understanding of tumor heterogeneity.

RESTRAINT: High cost of single-cell analysis products

The high costs of single-cell analysis products present significant obstacles for emerging markets and research institutions in developing countries. These regions often face financial limitations, currency fluctuations, and limited access to resources, making it even more challenging to invest in expensive single-cell analysis technologies. The cost implications of single-cell analysis products can hamper collaborations among research institutions. Sharing data and replicating experiments become complex when the required instruments and reagents are costly and not universally accessible.

OPPORTUNITY: High growth potential of single-cell sequencing

Single-cell sequencing offers exceptional resolution, allowing researchers to capture the cellular heterogeneity present within complex biological systems. Unlike traditional bulk sequencing methods that provide averaged results, single-cell sequencing enables the identification and analysis of individual cells. This improved resolution empowers researchers to uncover rare cell types, identify subpopulations, and explore dynamic cellular states, leading to a deeper understanding of biological processes and disease mechanisms.

CHALLENGE: Standardization of Protocols and Data Integration

Single-cell analysis encompasses a wide range of techniques and protocols, from cell isolation and sample preparation to data analysis. There is a lack of standardized protocols across different laboratories and platforms, leading to variability and inconsistency in experimental procedures. This makes it challenging to compare and integrate data generated from different studies, hindering reproducibility and data sharing. Single-cell analysis generates large and complex datasets, including gene expression profiles, genomic variations, and phenotypic data at the individual cell level. Integrating and comparing these datasets across studies can be challenging due to differences in experimental conditions, technologies, and analysis pipelines. Harmonizing data from different sources and platforms is crucial for meaningful cross-study comparisons and to unlock the full potential of single-cell analysis.

The consumables segment dominated the single cell analysis industry in 2022.

Based on product, the single cell analysis market is broadly segmented into consumables and instruments. In 2022, consumables accounted for the dominant share of the single cell analysis industry. This segment's large share can be attributed to factors such as the preference of researchers for the single-cell analysis techniques and associated consumables; and repetitive purchase of consumables compared to instruments. Furthermore, the increasing adoption of high-throughput technologies is likely to upsurge the growth of the segment.

The research applications segment of single cell analysis industry is expected to grow at the highest CAGR during the forecast period.

Based on application, the single cell analysis market is segmented into research applications, and medical applications. The research applications segment is expected to register the highest CAGR during the forecast period. Advancement in single-cell technologies is one of the factors driving the market growth.

North America dominated single cell analysis industry in 2022.

Geographically, the single cell analysis market is divided geographically into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America held the greatest market share for single-cell analysis in 2022, followed by Europe and the Asia-Pacific region. A number of variables, including strong research infrastructure, high investment in research and development, and presence of key players, account for the major share of the American market.

To know about the assumptions considered for the study, download the pdf brochure

Key players in the single cell analysis market are Becton, Dickinson and Company (US), Danaher Corporation (US), Merck KGaA (Germany), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (US), 10x Genomics (US), Promega Corporation (US), Illumina, Inc. (US), Bio-Rad Laboratories (US), Standard BioTools (US), Agilent Technologies, Inc. (US), Tecan Group Ltd. (Switzerland), Sartorius AG (Germany), DiaSorin S.p.A. (Italy), Takara Bio, Inc. (Japan), Fluxion Biosciences (US), Menarini Silicon Biosystems Inc. (Italy), bioMérieux SA (France), Oxford Nanopore Technologies (UK), Cytek Biosciences (US), Corning Incorporated (US), Apogee Flow Systems Ltd. (UK), NanoCellect Biomedical (US), RareCyte, Inc. (US), and On-chip Biotechnologies Co., Ltd. (Japan).

Scope of the Single Cell Analysis Industry

This report categorizes the single cell analysis market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Consumables
• Beads
• Microplates
• Reagents
• Assay Kits
• Immunoassays
• Cell-based Assays
• Other Consumables
• Instruments
• Flow Cytometers
• NGS Systems
• PCR Instruments
• Spectrophotometers
• Microscopes
• Cell Counters
• HCS Systems
• Microarrays
• Other Instruments

By Cell Type

• Human Cells
• Animal Cells
• Microbial Cells

By Technique

• Flow Cytometry
• Next-generation Sequencing
• Polymerase Chain Reaction
• Microscopy
• Mass Spectrometry
• Other Techniques

By Application

• Research Applications
• Cancer
• Immunology
• Neurology
• Stem Cell
• Other Research Applications
• Medical Applications
• Noninvasive Prenatal Diagnosis
• in Vitro Fertilization
• Circulating Tumor Cell Detection

By End users

• Academic & Research Laboratories
• Biotechnology & Pharmaceutical Companies
• Hospitals & Diagnostic Laboratories
• Cell Banks & IVF Centers

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • Japan
  • China
  • India
  • Rest of Asia Pacific (RoAPAC)
• Latin America
• MEA

Recent Developments of Stem Cell Analysis Industry

• In May 2023, Becton, Dikinson and Company launched BD FACSDiscover S8 Cell Sorter, new-to-world cell sorting instrument featuring two breakthrough technologies that enable researchers to uncover more detailed information about cells that was previously invisible in traditional flow cytometry experiments.
• In June 2022, Merck KGaA collaborated with Agilent Technologies to advance Process Analytical Technologies (PAT). PAT, which is strongly encouraged by global regulatory authorities, is a key enabler for real-time release and Bioprocessing 4.0.
• In August 2021, Danaher Corporation acquired the Aldevron. As previously announced, Aldevron will operate as a standalone operating company and brand within Danaher's Life Sciences segment.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst